“The combination of in vitro ADME, in vitro toxicology, and Cyprotex’s proprietary predictive modelling and proprietary CellCiphrTM technology acquired [with Apredica] from Cellumen gives Cyprotex’s customers access to the most extensive and advanced portfolio of early ADME Tox services on the market today,” said Anthony Baxter, Cyprotex’s CEO.
Cyprotex’s new facility houses the latest technology in multi-parametric automated fluorescent imaging and cellular analysis enabling Cyprotex, the preclinical ADME tox services company, to offer a range of services including reactive metabolite detection, phospholipidosis, and toxicological gene regulation.
“Drug toxicity and drug-induced liver injury in particular, is a major reason for failures in clinical trials and for the withdrawal of previously approved drugs from the market,” said Baxter, adding: “Toxicity is the most costly problem in drug development today.”